Patients, disease, and transplant characteristics
| Patients . | N = 77 . |
|---|---|
| Age, median (range), y | 53 (19-65) |
| Patient sex, n (%) | |
| Male/female | 45 (58.4%)/32 (41.6%) |
| ECOG, n (%) | |
| 0 | 64 (83.1%) |
| >0 | 11 (14.3%) |
| Unknown | 2 (2.6%) |
| HCT-CI, n (%) | |
| 0-2 | 64 (83.1%) |
| ≥3 | 13 (16.9%) |
| Disease | |
| AML, n (%) | 64 (83.1%) |
| WHO classification, n (%) | |
| AML with recurrent genetic abnormalities | 16 (25.0%) |
| AML with myelodysplasia-related changes | 15 (23.4%) |
| Therapy-related myeloid neoplasm | 4 (6.3%) |
| AML, NOS | 28 (43.8%) |
| Myeloid sarcoma | 1 (1.6%) |
| Cytogenetic risk (ELN 2022) , n (%) | |
| Favorable | 14 (21.9%) |
| Intermediate | 37 (57.8%) |
| Adverse | 13 (20.3%) |
| Molecular markers | |
| FLT 3 | 15 |
| NPM1 | 19 |
| IDH1/IDH2 | 8 |
| ASXL1 | 3 |
| AML1/ETO RUNX1::RUNX1T1 | 2 |
| BCR::ABL1 | 2 |
| No CR postinduction therapy | 15 (23.4%) |
| ≥2 CR | 11 (17%) |
| MRD positive at transplant, n (%) | |
| Molecular markers | 14/64 (21%) |
| NPM | 11 (17%) |
| AML1/ETO | 2 (3%) |
| bcr/abl | 1 (1%) |
| IF | 14/64 (21%) |
| MDS, n (%) | 13 (16.9%) |
| WHO classification, n (%) | |
| MDS with single lineage dysplasia | 2 (15.4%) |
| MDS with multilineage dysplasia | 2 (15.4%) |
| MDS with excess blasts | 6 (46.1%) |
| MDS with isolated del(5q) | 1 (7.7%) |
| MDS, unclassifiable | 2 (15.4%) |
| HSCT up-front | 5 |
| Transplant and donors | |
| Diagnosis: transplant, median (range), d | 202 (115-1482) |
| Year of the transplant, n (%) | |
| 2020 | 21 (27.3%) |
| 2021 | 32 (41.6%) |
| 2022 | 24 (31.2%) |
| Conditioning Bu4Flu, n (%) | 77 (100%) |
| Donor age, median (range), y | 29 (18-62) |
| Donor sex, n (%) | |
| Male/female | 51 (66.2%)/26 (33.8%) |
| Donor/recipient sex mismatch, n (%) | |
| Male/male | 31 (40.2%) |
| Male/female | 14 (18.2%) |
| Female/male | 20 (26.0%) |
| Female/female | 12 (15.6%) |
| CMV serostatus, n (%) | |
| +/+ | 34 (44.1%) |
| –/+ | 19 (24.7%) |
| +/– | 9 (11.7%) |
| –/– | 6 (7.8%) |
| Missing | 9 (11.7%) |
| Stem cell source, n (%) | |
| PB | 72 (93.5%) |
| BM | 5 (6.5%) |
| Cell dose | |
| PB median (range), CD34+, ×106/kg | 5.9 (2.2-12.2) |
| BM median (range), CD34+, ×106/kg | 2.3 (1.4-5.3) |
| Donor HLA mismatches 7/8, n (%) | 77 (100%) |
| HLA class I mismatch (A, B, C) | 72 (93.5%) |
| HLA class II mismatch (DRB1) | 3 (4%) |
| Missing | 2 (2.5%) |
| Patients . | N = 77 . |
|---|---|
| Age, median (range), y | 53 (19-65) |
| Patient sex, n (%) | |
| Male/female | 45 (58.4%)/32 (41.6%) |
| ECOG, n (%) | |
| 0 | 64 (83.1%) |
| >0 | 11 (14.3%) |
| Unknown | 2 (2.6%) |
| HCT-CI, n (%) | |
| 0-2 | 64 (83.1%) |
| ≥3 | 13 (16.9%) |
| Disease | |
| AML, n (%) | 64 (83.1%) |
| WHO classification, n (%) | |
| AML with recurrent genetic abnormalities | 16 (25.0%) |
| AML with myelodysplasia-related changes | 15 (23.4%) |
| Therapy-related myeloid neoplasm | 4 (6.3%) |
| AML, NOS | 28 (43.8%) |
| Myeloid sarcoma | 1 (1.6%) |
| Cytogenetic risk (ELN 2022) , n (%) | |
| Favorable | 14 (21.9%) |
| Intermediate | 37 (57.8%) |
| Adverse | 13 (20.3%) |
| Molecular markers | |
| FLT 3 | 15 |
| NPM1 | 19 |
| IDH1/IDH2 | 8 |
| ASXL1 | 3 |
| AML1/ETO RUNX1::RUNX1T1 | 2 |
| BCR::ABL1 | 2 |
| No CR postinduction therapy | 15 (23.4%) |
| ≥2 CR | 11 (17%) |
| MRD positive at transplant, n (%) | |
| Molecular markers | 14/64 (21%) |
| NPM | 11 (17%) |
| AML1/ETO | 2 (3%) |
| bcr/abl | 1 (1%) |
| IF | 14/64 (21%) |
| MDS, n (%) | 13 (16.9%) |
| WHO classification, n (%) | |
| MDS with single lineage dysplasia | 2 (15.4%) |
| MDS with multilineage dysplasia | 2 (15.4%) |
| MDS with excess blasts | 6 (46.1%) |
| MDS with isolated del(5q) | 1 (7.7%) |
| MDS, unclassifiable | 2 (15.4%) |
| HSCT up-front | 5 |
| Transplant and donors | |
| Diagnosis: transplant, median (range), d | 202 (115-1482) |
| Year of the transplant, n (%) | |
| 2020 | 21 (27.3%) |
| 2021 | 32 (41.6%) |
| 2022 | 24 (31.2%) |
| Conditioning Bu4Flu, n (%) | 77 (100%) |
| Donor age, median (range), y | 29 (18-62) |
| Donor sex, n (%) | |
| Male/female | 51 (66.2%)/26 (33.8%) |
| Donor/recipient sex mismatch, n (%) | |
| Male/male | 31 (40.2%) |
| Male/female | 14 (18.2%) |
| Female/male | 20 (26.0%) |
| Female/female | 12 (15.6%) |
| CMV serostatus, n (%) | |
| +/+ | 34 (44.1%) |
| –/+ | 19 (24.7%) |
| +/– | 9 (11.7%) |
| –/– | 6 (7.8%) |
| Missing | 9 (11.7%) |
| Stem cell source, n (%) | |
| PB | 72 (93.5%) |
| BM | 5 (6.5%) |
| Cell dose | |
| PB median (range), CD34+, ×106/kg | 5.9 (2.2-12.2) |
| BM median (range), CD34+, ×106/kg | 2.3 (1.4-5.3) |
| Donor HLA mismatches 7/8, n (%) | 77 (100%) |
| HLA class I mismatch (A, B, C) | 72 (93.5%) |
| HLA class II mismatch (DRB1) | 3 (4%) |
| Missing | 2 (2.5%) |
CMV, cytomegalovirus; ECOG, Eastern Cooperative Oncology Group; HCT-CI, hematopoietic cell transplantation–comorbidity index; IF, immunophenotyping; NOS, not otherwise specified; PB, peripheral blood; WHO, World Health Organization.